Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration

Pharmaceutical Investing

Paratek Pharmaceuticals (Nasdaq:PRTK) announced today that on February 2, 2018, it completed the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the Company’s once-daily oral and IV formulations of its broad-spectrum investigational antibiotic, omadacycline. As quoted in the press release: “The completion of our NDA submissions marks …

Paratek Pharmaceuticals (Nasdaq:PRTK) announced today that on February 2, 2018, it completed the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the Company’s once-daily oral and IV formulations of its broad-spectrum investigational antibiotic, omadacycline.

As quoted in the press release:

“The completion of our NDA submissions marks a significant milestone for Paratek and we are deeply grateful to the patients, investigators, and entire Paratek team for their commitment to advancing omadacycline’s development path to this major milestone,” said Evan Loh, MD, President, COO & CMO of Paratek.

Click here to read the full press release.

The Conversation (0)
×